The stock of Taysha Gene Therapies Inc (NASDAQ: TSHA) has increased by 2596309 when compared to last closing price of 2.49.Despite this, the company has seen a loss of -7.42% in its stock price over the last five trading days. globenewswire.com reported 2025-06-06 that DALLAS, June 06, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha’s Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company’s common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA) Right Now?
Moreover, the 36-month beta value for TSHA is 1.01. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 213.50M and currently, short sellers hold a 14.98% of that float. On June 25, 2025, TSHA’s average trading volume was 3.82M shares.
TSHA’s Market Performance
TSHA’s stock has seen a -7.42% decrease for the week, with a -16.84% drop in the past month and a 42.77% gain in the past quarter. The volatility ratio for the week is 3.28%, and the volatility levels for the past 30 days are at 4.28% for Taysha Gene Therapies Inc. The simple moving average for the past 20 days is -10.31% for TSHA’s stock, with a 19.42% simple moving average for the past 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with BMO Capital Markets repeating the rating for TSHA by listing it as a “Outperform.” The predicted price for TSHA in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on June 27, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $9. The rating they have provided for TSHA stocks is “Overweight” according to the report published on April 09th, 2024.
Jefferies gave a rating of “Hold” to TSHA, setting the target price at $1.50 in the report published on February 01st of the previous year.
TSHA Trading at 2.74% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.40% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 750,000 shares at the price of $2.75 back on May 30 ’25. After this action, Manning Paul B now owns 2,841,704 shares of Taysha Gene Therapies Inc, valued at $2,062,500 using the latest closing price.
Manning Paul B, the 10% Owner of Taysha Gene Therapies Inc, purchase 1,333,333 shares at $2.25 during a trade that took place back on Jun 27 ’24, which means that Manning Paul B is holding 1,333,333 shares at $2,999,999 based on the most recent closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -12.26 for the present operating margin
- 0.73 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -12.01. The total capital return value is set at -0.76. Equity return is now at value -159.34, with -59.56 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -4.88. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -1639.81.
Currently, EBITDA for the company is -87.95 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 72.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.35.
Conclusion
To wrap up, the performance of Taysha Gene Therapies Inc (TSHA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
